Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi Sells 5,827 Shares

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 5,827 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $27.31, for a total transaction of $159,135.37. Following the transaction, the chief financial officer now directly owns 141,846 shares in the company, valued at $3,873,814.26. The trade was a 3.95 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Balaji Gandhi also recently made the following trade(s):

• On Wednesday, January 15th, Balaji Gandhi sold 836 shares of Phreesia stock. The shares were sold at an average price of $26.98, for a total transaction of $22,555.28.
• On Monday, January 6th, Balaji Gandhi sold 3,195 shares of Phreesia stock. The stock was sold at an average price of $26.61, for a total transaction of $85,018.95.

Phreesia Stock Performance

NYSE:PHR opened at $27.89 on Friday. The firm’s 50-day moving average is $24.00 and its 200-day moving average is $23.00. The company has a market cap of $1.62 billion, a price-to-earnings ratio of -18.98 and a beta of 0.94. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74. Phreesia, Inc. has a 52-week low of $17.07 and a 52-week high of $29.16.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.04. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The firm had revenue of $106.80 million for the quarter, compared to analyst estimates of $106.33 million. During the same period in the previous year, the company posted ($0.58) earnings per share. The company’s quarterly revenue was up 16.6% compared to the same quarter last year. Equities research analysts anticipate that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have commented on PHR shares. Robert W. Baird lowered their target price on Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. Truist Financial increased their price target on shares of Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Royal Bank of Canada raised Phreesia from a “sector perform” rating to an “outperform” rating and raised their price objective for the company from $24.00 to $32.00 in a research note on Wednesday, January 8th. JMP Securities reaffirmed a “market outperform” rating and set a $30.00 target price on shares of Phreesia in a research report on Tuesday, December 10th. Finally, KeyCorp lifted their price target on shares of Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Wednesday, January 8th. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $31.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of PHR. R Squared Ltd bought a new stake in Phreesia in the 4th quarter valued at $30,000. International Assets Investment Management LLC boosted its position in shares of Phreesia by 2,179.7% during the 3rd quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock valued at $33,000 after acquiring an additional 1,395 shares in the last quarter. Lombard Odier Asset Management USA Corp bought a new stake in Phreesia in the second quarter valued at about $202,000. Point72 DIFC Ltd acquired a new position in Phreesia in the second quarter worth about $209,000. Finally, XTX Topco Ltd bought a new position in Phreesia during the third quarter worth about $247,000. 92.10% of the stock is owned by institutional investors.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.